Drug Profile
Research programme: Neurological disorders therapeutics - Asceneuron
Alternative Names: O-GlcNAcase inhibitors - AceneuronLatest Information Update: 28 Aug 2022
Price :
$50
*
At a glance
- Originator Merck Serono
- Developer Asceneuron
- Class Antidementias; Neuroprotectants; Small molecules
- Mechanism of Action Hexosaminidase C inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Alzheimer's disease; Dementia; Progressive supranuclear palsy
Most Recent Events
- 28 Aug 2022 No recent reports of development identified for preclinical development in Dementia in Switzerland (PO)
- 28 Nov 2020 No recent reports of development identified for preclinical development in Progressive-supranuclear-palsy in Switzerland (PO)
- 28 Nov 2018 No recent reports of development identified for preclinical development in Alzheimer's-disease in Switzerland (PO)